Pitchkit
  • Docs
  • Pricing
  • Blog
  • Tools
  • Investors
Sign inGet started
Pitchkit

Structure and stress-test your pitch with workflows built from 6+ years of VC dealflow.

Product

  • Overview
  • Pitch deck feedback
  • Pitch deck generator
  • Templates
  • Pricing

Resources

  • Learn
  • Pitch by stage
  • Slide guides
  • Docs
  • Glossary
  • Free tools

Company

  • About
  • Blog
  • Changelog
  • Contact
  • Privacy policy

Ready to pitch?

Start building your investor-ready pitch today. Free forever, no credit card required.

Start free

© 2026 Pitchkit / edgelord.tech

All systems operational
Pitchkit
Back to investor directory
Venture capital
France

Kurma Partners

Investment focus

Sectors

Biotech
Healthtech

Investment stages

Seed
Series A
Series B

Geographic focus

Europe

Investment thesis

European specialist biotech VC (part of Eurazeo group) backing companies from inception through clinical development, with particular strength in university and research institute spinouts in France and Germany.

Typical check size

€3M – €20M

Fund size: €250M (Biofund IV target)

Browse similar check sizes →

Portfolio highlights

Amolyt Pharma - rare endocrine disease company; co-led from Series A; acquired by AstraZeneca for $1.05B
SciRhom - autoimmune disease biotech targeting iRhom2 pathway
Memo Therapeutics - natural immunity-inspired antibody therapeutics company

Contact

www.kurmapartners.com
France

Research with AI

Learn more about Kurma Partners using AI:

Ask ChatGPTAsk Perplexity

Pitch guides

Learn what Kurma Partners and similar investors look for:

Biotech pitch guideHealthtech pitch guide

More investors in France

360 CapitalAlvenAndera PartnersBlackFin Capital PartnersView all in France

Related resources

Seed fundraising guideSeed pitch deck guideSeries A fundraising guideSeries A pitch deck guideSeries B fundraising guideGlossary: Term sheet
Fundraising in France

Tips, programs, and cultural notes

More Biotech investors

AbingworthACF InvestorsAhren Innovation CapitalAlmi Invest GreenTechView all Biotech investors